TY - JOUR
T1 - Quantitative flow ratio versus fractional flow reserve for guiding percutaneous coronary intervention
T2 - design and rationale of the randomised FAVOR III Europe Japan trial
AU - Andersen, Birgitte Krogsgaard
AU - Sejr-Hansen, Martin
AU - Westra, Jelmer
AU - Campo, Gianluca
AU - Efterkhari, Ashkan
AU - Tu, Shengxian
AU - Escaned, Javier
AU - Koltowski, Lukasz
AU - Stähli, Barbara
AU - Erglis, Andrejs
AU - Jaruševičius, Gediminas
AU - Žiubrytė, Greta
AU - Råmunddal, Truls
AU - Liu, Tommy
AU - Wijns, William
AU - Landmesser, Ulf
AU - Maillard, Luc
AU - Matsuo, Hitoshi
AU - Christiansen, Evald Høj
AU - Holm, Niels Ramsing
N1 - Publisher Copyright:
© 2023 Europa Group. All rights reserved.
PY - 2023/4
Y1 - 2023/4
N2 - Quantitative flow ratio (QFR) is a computation of fractional flow reserve (FFR) based on invasive coronary angiographic images. Calculating QFR is less invasive than measuring FFR and may be associated with lower costs. Current evidence supports the call for an adequately powered randomised comparison of QFR and FFR for the evaluation of intermediate coronary stenosis. The aim of the FAVOR III Europe Japan trial is to investigate if a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with a standard FFR-guided strategy in the evaluation of patients with intermediary coronary stenosis. FAVOR III Europe Japan is an investigator-initiated, randomised, clinical outcome, non-inferiority trial scheduled to randomise 2,000 patients with either 1) stable angina pectoris and intermediate coronary stenosis, or 2) indications for functional assessment of at least 1 non-culprit lesion after acute myocardial infarction. Up to 40 international centres will randomise patients to either a QFR-based or a standard FFR-based diagnostic strategy. The primary endpoint of major adverse cardiovascular events is a composite of all-cause mortality, any myocardial infarction, and any unplanned coronary revascularisation at 12 months. QFR could emerge as an adenosine- and wire-free alternative to FFR, making the functional evaluation of intermediary coronary stenosis less invasive and more cost-effective.
AB - Quantitative flow ratio (QFR) is a computation of fractional flow reserve (FFR) based on invasive coronary angiographic images. Calculating QFR is less invasive than measuring FFR and may be associated with lower costs. Current evidence supports the call for an adequately powered randomised comparison of QFR and FFR for the evaluation of intermediate coronary stenosis. The aim of the FAVOR III Europe Japan trial is to investigate if a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with a standard FFR-guided strategy in the evaluation of patients with intermediary coronary stenosis. FAVOR III Europe Japan is an investigator-initiated, randomised, clinical outcome, non-inferiority trial scheduled to randomise 2,000 patients with either 1) stable angina pectoris and intermediate coronary stenosis, or 2) indications for functional assessment of at least 1 non-culprit lesion after acute myocardial infarction. Up to 40 international centres will randomise patients to either a QFR-based or a standard FFR-based diagnostic strategy. The primary endpoint of major adverse cardiovascular events is a composite of all-cause mortality, any myocardial infarction, and any unplanned coronary revascularisation at 12 months. QFR could emerge as an adenosine- and wire-free alternative to FFR, making the functional evaluation of intermediary coronary stenosis less invasive and more cost-effective.
KW - clinical research
KW - clinical trials
KW - fractional flow reserve
KW - other imaging modalities
UR - http://www.scopus.com/inward/record.url?scp=85150373594&partnerID=8YFLogxK
U2 - 10.4244/EIJ-D-21-00214
DO - 10.4244/EIJ-D-21-00214
M3 - Article
C2 - 36648404
AN - SCOPUS:85150373594
SN - 1774-024X
VL - 18
SP - E1357-E1364
JO - EuroIntervention
JF - EuroIntervention
IS - 16
ER -